^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIF5B-RET fusion

    i
    Entrez ID:
    5979; 3799
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity (NCT01639508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/26/2023
    Initiation :
    07/01/2012
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    RET • ROS1 • KIF5B • AXL • NTRK
    |
    RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion
    |
    Cabometyx (cabozantinib tablet)
    AUY922 in Patient With Stage IV NSCLC (NCT01922583)
    Phase 2
    National Taiwan University Hospital
    Completed
    Last update posted :
    07/18/2018
    Initiation :
    01/01/2014
    Primary completion :
    02/01/2017
    Completion :
    02/01/2017
    EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2
    |
    BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation
    |
    luminespib (AUY922)